New anesthetic may offer safer sedation for heart valve patients

NCT ID NCT05881291

Completed Symptom relief Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested a new sedative called ciprofol against the standard drug propofol for general anesthesia in 124 older adults undergoing transcatheter aortic valve replacement (TAVR). The goal was to see if ciprofol causes fewer episodes of low blood pressure after anesthesia. Researchers measured blood pressure changes in the first 15 minutes after sedation and tracked side effects like injection pain.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: ciprofol
What this could lead to: If successful, ciprofol could offer a safer alternative to propofol for anesthesia in heart valve replacement, with fewer drops in blood pressure.
What could go wrong: This is a small, completed phase 4 trial with 124 patients. Results may not apply to all patients, and ciprofol's benefits over propofol may be modest.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for AORTIC VALVE STENOSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

aortic valve stenosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

GENERAL ANESTHESIA HEMODYNAMICS POST-INDUCTION HYPOTENSION TRANSCATHETER AORTIC VALVE REPLACEMENT

Contacts and locations

Locations

The Second Affiliated Hospital of Zhejiang University anesthesiology department

Hangzhou, Zhejiang, 310000, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.